NCT00515385View on ClinicalTrials.gov

A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions
West Nile Virus
Interventions
DRUG

MGAWN1

"Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg"

DRUG

MGAWN1

Single IV dose

OTHER

Placebo

Single IV dose

Trial Locations (1)

21225

PAREXEL Phase 1 Unit, Baltimore

Sponsors

Lead Sponsor

MacroGenics
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

MacroGenics

INDUSTRY

NCT00515385 - A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults | Biotech Hunter | Biotech Hunter